In 2003, the World Health Organization identified obesity as a growing global threat affecting more than 300 million people worldwide. Although it is commonly believed that obese individuals can overcome their condition by simply eating less and exercising more, compelling scientific data suggest that the heritability of obesity is greater than breast cancer, heart disease, or schizophrenia. Morbid obesity is considered as the disease of the twenty-first century, with the affected individuals at higher risk for diabetes, heart disease, hypertension and cancer, collectively known as metabolic syndrome.
Shp2, a Src homology 2-containing tyrosine phosphatase, was discovered by Dr. Feng and others over a decade ago. It is present in each cell type in the body and is implicated in a variety of growth factor or cytokine pathways present in these cells.
The physiological function of Shp2 is largely unknown. Whether it is active in multiple pathways or focused on a single pathway remains to be seen. In recent years, in vitro experiments suggest that Shp2 plays a role in regulating the protein leptin. Leptin, produced in fat cells, is a hormone that regulates body weight, metabolism, and reproduction. The primary action site for leptin is within the hypothalamus, located in the forebrain.
Dr. Feng and his colleagues took the investigation to the next level by looking at the role of Shp-2 in live mice. They bred a special kind of mouse in which the elimination of Shp-2 was confined to the mouse's forebrain by using a highly advanced genetic engineering technique called "cell-type specific gene knockout". The progeny were mice with early-onset obesity that had increased levels of leptin, insulin, glucose, and triglycerides. Furthermore, the mice could gain weight by eating normal amounts of food, which supports a role for Shp-2 in metabolism.
"Shp-2 has different functions in each cell," says Dr. Feng. "We found that in adult neuoronal cells, it's important function is to control metabolism. This hypothesis will be tested further, but it appears to present a target for the design of new anti-obesity drugs that could help individuals suffering from obesity by increasing their sensitivity to leptin."
Dr. Feng is an Associate Professor in the Burnham Institute's Program on Signal Transduction.
This work was supported by grants from the National Institutes of Health. Dr. Feng acknowledges with appreciation the American Diabetes Foundation, which supported the research that led to his discovery of the Shp2 tyrosine phosphatase early in his career.
The Burnham Institute is an independent, nonprofit, public benefit organization dedicated to biomedical research. The Institute employs over 625 persons and is home to three research centers, including a Cancer Center sponsored by the National Cancer Institute, the Del E. Webb Center for Neuroscience and Aging, which focuses on diseases such as stroke, Alzheimer's, Parkinson's, and other neurodegenerative diseases, and the recently established Infectious and Inflammatory Disease Center. The Institute operates on an annual budget of over $68 Million. These funds are derived primarily from federal grants. Other important sources of funding include private foundations, philanthropy, and technology transfer. To learn more about The Burnham Institute, visit our website at www.burnham.org.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.